TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES
Disclosed herein are methods of reducing risk of cardiovascular event in patients with coronary artery disease and/or diabetes being treated with aspirin and/or a P2Y12 inhibitor, by administering to a patient a therapeutically effective amount of a pharmaceutically acceptable form of a compound which is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoic acid, at a time when the patient has an elevated epinephrine level.